---
title: "Oncolytics Biotech Inc. (ONCY.US) — 公司概况"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/ONCY.US/overview.md"
symbol: "ONCY.US"
name: "Oncolytics Biotech Inc."
parent: "https://longbridge.com/zh-CN/quote/ONCY.US.md"
datetime: "2026-04-15T09:33:51.432Z"
locales:
  - [en](https://longbridge.com/en/quote/ONCY.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ONCY.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ONCY.US/overview.md)
---

# Oncolytics Biotech Inc. (ONCY.US) — 公司概况

## 基本信息

| 项目 | 详情 |
|------|--------|
| 行业 | 生物技术 |
| 交易所 | US Market |
| 地址 | 322 11th Avenue SW, Suite 804, Calgary, Alberta, Canada |
| 官网 | [oncolyticsbiotech.com](https://oncolyticsbiotech.com) |

## 公司简介

Oncolytics Biotech Inc.是一家临床阶段的生物制药公司，专注于肿瘤治疗的研究、开发和商业化。该公司开发了 pelareorep，这是一种通过静脉输注的免疫治疗药物，用于治疗激素受体阳性/人类表皮生长因子 2 阴性晚期和转移性乳腺癌、转移性胰腺导管腺癌和肛门癌。它与罗氏控股公司（Roche Holding AG）达成协议，供应其免疫检查点抑制剂阿特珠单抗（atezolizumab），用于其正在进行的赞助研究。Oncolytics Biotech Inc

## 核心管理层

| 名称 | 职位 |
|------|-------|
| Jared Kelly | CEO & Director |
| Wayne F. Pisano | Chairman of the Board |
| Kirk J. Look | Chief Financial Officer |
| Thomas C. Heineman | Chief Medical Officer |
| John McAdory | Executive VP of Strategy & Operations |
| Allison Hagerman | Chief Technology Officer |
| Angela Frances Holtham | Independent Director |
| Deborah M. Brown | Independent Director |
| Jonathan M. N. Rigby | Independent Director |

## 主要股东

| 名称 | 占比 | 报告日期 |
|------|-------|-------------|
| Bernd Robert Seizinger | 0.49% | 2026-02-12 |
| Wayne F. Pisano | 0.42% | 2026-02-12 |
| Morgan Stanley | 0.37% | 2025-12-31 |
| Sandbox Financial Partners, LLC | 0.34% | 2026-03-31 |
| Kirk J. Look | 0.25% | 2026-02-12 |
| Thomas C. Heineman | 0.24% | 2026-02-12 |
| Marshall Wace LLP | 0.23% | 2025-12-31 |
| Seeds Investor LLC | 0.22% | 2025-12-31 |
| International Assets Investment Management, LLC | 0.18% | 2025-12-31 |
| Angela Frances Holtham | 0.16% | 2026-01-01 |


---

> **免责声明: 本文仅供参考，不构成任何投资建议。**